ArticleAnalytical chemistry2025
New Chemotherapeutic Approaches to Treatment of Mesenchymal Triple-Negative Breast Cancer-Sensitive and Resistant to Cisplatin: Assessment of Cellular Response by Vibrational Microspectroscopy.
Article in Analytical chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Triple-negative breast cancer (TNBC) is the most aggressive type of breast tumor with the worst prognosis. New chemotherapeutic agents against TNBC are essential, aiming at a higher efficacy regarding cell growth inhibition and decreased angiogenesis and invasiveness coupled to lower acquired resistance and deleterious side effects. In this study, Raman and Fourier Transform Infrared (FTIR) microspectroscopies were applied to assess the impact of a trinuclear palladium-spermidine complex on human healthy and mesenchymal TNBC cells, with the results being compared to the clinically used drug cisplatin. To understand the metabolic impact of the drugs at the molecular level and identify the main biomarkers, unsupervised multivariate analysis of the data (Principal Component Analysis and Hierarchical Cluster Analysis) was applied to the vibrational data. The results revealed that the new palladium (Pd) agent had a higher effect on the cellular lipids relative to the platinum (Pt) compound (cisplatin), while the latter showed a stronger impact on the proteins. Besides lipids, Pd-agent showed a higher impact in conformational changes from the B-DNA native conformation to either Z- or A-DNA. This suggests the occurrence of distinct pathways of cytotoxicity for these metal complexes. Also, when comparing cisplatin-sensitive to cisplatin-resistant cells, Pd-agent had a more significant impact on νOPO
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.